Taxanes in cancer treatment: Activity, chemoresistance and its overcoming

L Mosca, A Ilari, F Fazi, YG Assaraf, G Colotti - Drug Resistance Updates, 2021 - Elsevier
Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets

J Kopecka, P Trouillas, AČ Gašparović, E Gazzano… - Drug resistance …, 2020 - Elsevier
Lipids, phospholipids and cholesterol in particular, are the predominant components of the
plasma membrane, wherein multidrug efflux transporters of the ATP-binding cassette (ABC) …

Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update

J Dong, Z Qin, WD Zhang, G Cheng, AG Yehuda… - Drug Resistance …, 2020 - Elsevier
The presence of multidrug resistance (MDR) in malignant tumors is one of the primary
causes of treatment failure in cancer chemotherapy. The overexpression of the ATP binding …

P-glycoprotein inhibition for optimal drug delivery

ML Amin - Drug target insights, 2013 - journals.sagepub.com
P-glycoprotein (P-gp), an efflux membrane transporter, is widely distributed throughout the
body and is responsible for limiting cellular uptake and the distribution of xenobiotics and …

Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy

R Silva, V Vilas-Boas, H Carmo… - Pharmacology & …, 2015 - Elsevier
Abstract P-glycoprotein (P-gp) is an ATP-dependent efflux pump encoded by the MDR1
gene in humans, known to mediate multidrug resistance of neoplastic cells to cancer …

P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement

MVS Varma, Y Ashokraj, CS Dey… - Pharmacological …, 2003 - Elsevier
Drug efflux pumps like P-glycoprotein (P-gp) and multidrug resistance (MDR) proteins were
recognized to posses functional role in determining the pharmacokinetics of drugs …

[PDF][PDF] The P-glycoprotein efflux pump: how does it transport drugs?

FJ Sharom - The Journal of membrane biology, 1997 - researchgate.net
The development of multidrug resistance (MDR) is a major obstacle in the chemotherapeutic
treatment of many human cancers, including colon, kidney and breast carcinomas …

[HTML][HTML] Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated …

I Genovese, A Ilari, YG Assaraf, F Fazi… - Drug Resistance Updates, 2017 - Elsevier
The development of drug resistance continues to be a dominant hindrance toward curative
cancer treatment. Overexpression of a wide-spectrum of ATP-dependent efflux pumps, and …

Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport

S Zhang, ME Morris - Journal of Pharmacology and Experimental …, 2003 - ASPET
Flavonoids are constituents of fruits, vegetables, and plant-derived beverages, as well as
components in herbal-containing dietary supplements. The objective of this investigation …

[HTML][HTML] Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis

B Zhitomirsky, YG Assaraf - Oncotarget, 2017 - ncbi.nlm.nih.gov
We have recently shown that hydrophobic weak base anticancer drugs are highly
sequestered in acidic lysosomes, inducing TFEB-mediated lysosomal biogenesis and …